Anavex Life Sciences Corp (AVXL)

[stealthways]

IMO the 273 plus patent is not as critical (being delayed a bit) as many have said here... An issued patent is not required for 273 plus to commence P3; and if approved Anavex can sell 273 and Aricept , separately (and I think even combined in a single capsule) all while waiting for the patent (in the unlikely event if it takes a long time to be issued).....Lastly, as I understand also, their current 273 patent will protect them in either scenario with both selling 273 alone or with aricept.... The only reason I was thinking the 273 plus patent is valuable is it helps them to isolate the AD market, from open label sales and partner AD separately from the other Dementia indications by not having 273 sold individually in any indications, to very much limit (or completely eliminate) open label sales ...